Kardigan
Biopharmaceutical company focused on developing targeted cardiovascular medicines. Uses an integrated approach combining translational biology, biomarker-driven and adaptive clinical trial designs, and AI/real-world data to accelerate discovery and development of therapies for heart diseases including dilated cardiomyopathy, calcific aortic valve stenosis, and severe hypertension.
Industries
Nr. of Employees
small (1-50)
Kardigan
West Coast: 131 Oyster Point Blvd., Second Floor, South San Francisco, CA 94080
Products
Soluble guanylate cyclase activator for moderate calcific aortic valve stenosis (Phase 3)
Oral small-molecule activator being evaluated to slow aortic valve calcium deposition, preserve cardiopulmonary function, and attenuate disease progression in moderate calcific aortic valve stenosis.
Direct myosin activator for genetic dilated cardiomyopathy (Phase 2b/3 planned)
Mechanism-specific therapy designed to restore myosin motor function and improve atrial and ventricular performance in patients with sarcomeric gene–driven dilated cardiomyopathy.
Angiotensinogen-targeting antisense oligonucleotide for uncontrolled/acute severe hypertension (Phase 2b)
Antisense oligonucleotide therapeutic designed to reduce hepatic angiotensinogen production, lower plasma angiotensinogen levels, and stabilize blood pressure in acute or uncontrolled hypertension settings.
Discovery-stage cardiovascular programs (undisclosed mechanisms)
Multiple early-stage discovery programs focused on novel cardiovascular targets and mechanisms to expand the company’s pipeline.
Soluble guanylate cyclase activator for moderate calcific aortic valve stenosis (Phase 3)
Oral small-molecule activator being evaluated to slow aortic valve calcium deposition, preserve cardiopulmonary function, and attenuate disease progression in moderate calcific aortic valve stenosis.
Direct myosin activator for genetic dilated cardiomyopathy (Phase 2b/3 planned)
Mechanism-specific therapy designed to restore myosin motor function and improve atrial and ventricular performance in patients with sarcomeric gene–driven dilated cardiomyopathy.
Angiotensinogen-targeting antisense oligonucleotide for uncontrolled/acute severe hypertension (Phase 2b)
Antisense oligonucleotide therapeutic designed to reduce hepatic angiotensinogen production, lower plasma angiotensinogen levels, and stabilize blood pressure in acute or uncontrolled hypertension settings.
Discovery-stage cardiovascular programs (undisclosed mechanisms)
Multiple early-stage discovery programs focused on novel cardiovascular targets and mechanisms to expand the company’s pipeline.
Expertise Areas
- Adaptive clinical trial management
- Translational research and disease modeling
- Cardiovascular drug discovery
- Biomarker discovery and analytical endpoint development
Key Technologies
- AI / machine learning platforms
- Real-world data integration
- Cellular disease models
- Animal models
News & Updates
Press release summarizing positive Phase 2 results for a soluble guanylate cyclase activator showing reductions in aortic valve calcium and improvements in ventricular structure and function.
Press release announcing Series B financing to advance late-stage cardiovascular development programs.
Press release summarizing Phase 2a results for a direct myosin activator showing improvements in atrial and ventricular function, supporting further development.
Press release summarizing positive Phase 2 results for a soluble guanylate cyclase activator showing reductions in aortic valve calcium and improvements in ventricular structure and function.
Press release announcing Series B financing to advance late-stage cardiovascular development programs.
Press release summarizing Phase 2a results for a direct myosin activator showing improvements in atrial and ventricular function, supporting further development.